| __timestamp | BeiGene, Ltd. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 5699000000 |
| Thursday, January 1, 2015 | 7311000 | 5001000000 |
| Friday, January 1, 2016 | 20097000 | 5002000000 |
| Sunday, January 1, 2017 | 62602000 | 4849000000 |
| Monday, January 1, 2018 | 195385000 | 4551000000 |
| Tuesday, January 1, 2019 | 388249000 | 4871000000 |
| Wednesday, January 1, 2020 | 600176000 | 7661000000 |
| Friday, January 1, 2021 | 990123000 | 7690000000 |
| Saturday, January 1, 2022 | 1277852000 | 7814000000 |
| Sunday, January 1, 2023 | 1504501000 | 7772000000 |
| Monday, January 1, 2024 | 8414000000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Bristol-Myers Squibb Company and BeiGene, Ltd. have taken different paths in optimizing these costs. Bristol-Myers Squibb, a giant in the industry, consistently maintained SG&A expenses around $5 billion to $8 billion annually. In contrast, BeiGene, a rising star, saw its SG&A costs skyrocket from a modest $7 million in 2014 to over $1.5 billion by 2023, reflecting its rapid expansion and aggressive market strategies.
While Bristol-Myers Squibb's expenses grew by approximately 36% over the decade, BeiGene's expenses surged by an astonishing 21,600%. This stark difference highlights the contrasting growth strategies of an established player versus an emerging contender. As the pharmaceutical landscape evolves, these trends offer valuable insights into strategic cost management.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company or BeiGene, Ltd.: Who Invests More in Innovation?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Cytokinetics, Incorporated
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
BeiGene, Ltd. or Wave Life Sciences Ltd.: Who Manages SG&A Costs Better?
BeiGene, Ltd. and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xencor, Inc.